hVIVO steadies outlook as diversification offsets slower growth

hVIVO PLC reported H1 revenue of £24.2 million and reaffirmed full-year guidance of £47 million revenue with a small adjusted loss, meeting expectations. However, the company significantly lowered its 2026 growth outlook to high single-digits from a 20-25% consensus, leading to analyst downgrades and a 2.2% share price decline. Despite this, diversification efforts through recent acquisitions contributed £5.5 million in sales, aiming to reduce reliance on its core human challenge trial business, with the current 1.2x sales valuation reportedly reflecting tempered expectations amidst a weak biotech funding environment.

Analysis

hVIVO PLC's half-year results present a mixed outlook, characterized by near-term stability but a significantly downgraded medium-term growth trajectory. The company met expectations with H1 revenue of £24.2 million and reaffirmed its full-year guidance for £47 million, supported by strong visibility with 90% of second-half revenues already contracted. A key strategic development is the successful integration of acquisitions CRS and Cryostore, which contributed £5.5 million in sales and are part of a deliberate effort to diversify away from the core human challenge trial business, currently impacted by a weak biotech funding environment. The primary concern, however, is the severe reduction in 2026 growth guidance to high single-digits, a stark contrast to the previous 20-25% consensus. This revision has prompted analysts to act, with Stifel cutting its target price to 10p and Peel Hunt re-basing its model to forecast breakeven in 2026. While the £40 million order book covers most of the current year's revenue, it is noted to be lighter than a year ago, reinforcing the slowdown narrative. The stock's modest 2.2% decline and a valuation of 1.2 times sales suggest the market has already priced in much of this caution.

Key Decisions for Investors

• Investors should weigh the security of near-term contracted revenue against the significant downgrade in 2026 growth guidance, which has reset medium-term expectations and introduced considerable forecast risk.
• Closely monitor the revenue contribution from the acquired CRS and Cryostore divisions, as their performance is now critical to offsetting the slowdown in the core challenge trial business and validating the company's diversification strategy.
• Recognize that while the 1.2x sales valuation appears to reflect the negative outlook, a re-rating of the stock is contingent on the company converting its pipeline into the large-scale contracts required to achieve profitability by 2027, as now modeled by analysts.